UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 1, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $560.05 ($67,206) on October 1, 2026; holds 333,823 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $561.68 ($44,934) on October 1, 2026; holds 333,743 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $563.31 ($90,130) on October 1, 2026; holds 333,583 after (Indirect).
- Open-market sale: disposed of 94 Common Stock at $567.90 ($53,383) on October 1, 2026; holds 333,489 after (Indirect).
- Open-market sale: disposed of 306 Common Stock at $569.65 ($174,314) on October 1, 2026; holds 333,183 after (Indirect).
- Open-market sale: disposed of 534 Common Stock at $570.55 ($304,673) on October 1, 2026; holds 332,649 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $571.52 ($182,888) on October 1, 2026; holds 332,329 after (Indirect).
- Open-market sale: disposed of 560 Common Stock at $572.86 ($320,803) on October 1, 2026; holds 331,769 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $573.62 ($160,615) on October 1, 2026; holds 331,489 after (Indirect).
- Open-market sale: disposed of 830 Common Stock at $574.94 ($477,204) on October 1, 2026; holds 330,659 after (Indirect).
- Open-market sale: disposed of 1,346 Common Stock at $575.90 ($775,165) on October 1, 2026; holds 329,313 after (Indirect).
- Open-market sale: disposed of 774 Common Stock at $576.91 ($446,525) on October 1, 2026; holds 328,539 after (Indirect).
- Open-market sale: disposed of 930 Common Stock at $577.93 ($537,477) on October 1, 2026; holds 327,609 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $579.02 ($185,286) on October 1, 2026; holds 327,289 after (Indirect).
- Open-market sale: disposed of 864 Common Stock at $580.20 ($501,291) on October 1, 2026; holds 326,425 after (Indirect).
- Open-market sale: disposed of 702 Common Stock at $581.21 ($408,012) on October 1, 2026; holds 325,723 after (Indirect).
- Open-market sale: disposed of 520 Common Stock at $582.24 ($302,765) on October 1, 2026; holds 325,203 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $583.28 ($233,313) on October 1, 2026; holds 324,803 after (Indirect).
- Open-market sale: disposed of 360 Common Stock at $584.66 ($210,478) on October 1, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 1, 2026; holds 318,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,476,462 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-01 | Open-market sale | Common Stock | 120 | $560 | $67.2K | 333,823 |
| 2026-10-01 | Open-market sale | Common Stock | 80 | $562 | $44.9K | 333,743 |
| 2026-10-01 | Open-market sale | Common Stock | 160 | $563 | $90.1K | 333,583 |
| 2026-10-01 | Open-market sale | Common Stock | 94 | $568 | $53.4K | 333,489 |
| 2026-10-01 | Open-market sale | Common Stock | 306 | $570 | $174.3K | 333,183 |
| 2026-10-01 | Open-market sale | Common Stock | 534 | $571 | $304.7K | 332,649 |
| 2026-10-01 | Open-market sale | Common Stock | 320 | $572 | $182.9K | 332,329 |
| 2026-10-01 | Open-market sale | Common Stock | 560 | $573 | $320.8K | 331,769 |
| 2026-10-01 | Open-market sale | Common Stock | 280 | $574 | $160.6K | 331,489 |
| 2026-10-01 | Open-market sale | Common Stock | 830 | $575 | $477.2K | 330,659 |
| 2026-10-01 | Open-market sale | Common Stock | 1,346 | $576 | $775.2K | 329,313 |
| 2026-10-01 | Open-market sale | Common Stock | 774 | $577 | $446.5K | 328,539 |
| 2026-10-01 | Open-market sale | Common Stock | 930 | $578 | $537.5K | 327,609 |
| 2026-10-01 | Open-market sale | Common Stock | 320 | $579 | $185.3K | 327,289 |
| 2026-10-01 | Open-market sale | Common Stock | 864 | $580 | $501.3K | 326,425 |
| 2026-10-01 | Open-market sale | Common Stock | 702 | $581 | $408.0K | 325,723 |
| 2026-10-01 | Open-market sale | Common Stock | 520 | $582 | $302.8K | 325,203 |
| 2026-10-01 | Open-market sale | Common Stock | 400 | $583 | $233.3K | 324,803 |
| 2026-10-01 | Open-market sale | Common Stock | 360 | $585 | $210.5K | 324,443 |
| 2026-10-01 | Option exercise/conversion | Stock Option | 9,500 | — | — | 318,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (9,500 shares) |
| 2026-10-01 | Open-market sale (120 shares) |
| 2026-10-01 | Open-market sale (80 shares) |
| 2026-10-01 | Open-market sale (160 shares) |
| 2026-10-01 | Open-market sale (94 shares) |
| 2026-10-01 | Open-market sale (306 shares) |
| 2026-10-01 | Open-market sale (534 shares) |
| 2026-10-01 | Open-market sale (320 shares) |
| 2026-10-01 | Open-market sale (560 shares) |
| 2026-10-01 | Open-market sale (280 shares) |
| 2026-10-01 | Open-market sale (830 shares) |
| 2026-10-01 | Open-market sale (1,346 shares) |
| 2026-10-01 | Open-market sale (774 shares) |
| 2026-10-01 | Open-market sale (930 shares) |
| 2026-10-01 | Open-market sale (320 shares) |
| 2026-10-01 | Open-market sale (864 shares) |
| 2026-10-01 | Open-market sale (702 shares) |
| 2026-10-01 | Open-market sale (520 shares) |
| 2026-10-01 | Open-market sale (400 shares) |
| 2026-10-01 | Open-market sale (360 shares) |
| 2026-10-01 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.